Table 2:

Adverse events

	Grade 1–2	Grade 3	Grade 4	Grade 5
Thrombocytopenia	20 (51%)	3 (8%)	0	0
Fatigue	20 (51%)	1(3%)	0	0
Neutropenia	13(33%)	2(5%)	5 (13%)	0
Bruising	20(51%)	0	0	0
Diarrhoea	18 (46%)	0	0	0
Infusion-related reaction	15(39%)	1(3%)	1(3%)	0
Anaemia	16(41%)	0	0	0
Cough	14(36%)	0	0	0
Rash	10 (26%)	3(8%)	0	0
Nausea	12 (31%)	0	0	0
Constipation	11 (28%)	0	0	0
Nasal congestion	10 (26%)	0	0	0
Gastroesophageal reflux disease	10 (26%)	0	0	0
Insomnia	9 (23%)	0	0	0
Myalgia	9(23%)	0	0	0
Arthralgia	8 (21%)	0	0	0
Abdominal pain	7(18%)	0	0	0
Anxiety	7(18%)	0	0	0
Dyspnea	7(18%)	0	0	0
Sinusitis	7(18%)	0	0	0
Alkaline phosphatase increased	5(13%)	1(3%)	0	0
Dizziness	6(15%)	0	0	0
Dry skin	6(15%)	0	0	0
Postnasal drip	6(15%)	0	0	0
Back pain	6(15%)	0	0	0
Weight loss	6(15%)	0	0	0
Hypocalcaemia	6(15%)	0	0	0
Hyperglycaemia	5 (13%)	0	0	0
Sore throat	5 (13%)	0	0	0
Hypertension	5(13%)	0	0	0
Lung infection	2(5%)	3(8%)	0	0
Mucositis oral	3(8%)	1(3%)	0	0
Aspartate aminotransferase increased	4 (10%)	0	0	0
Headache	4 (10%)	0	0	0
Bloating	4 (10%)	0	0	0
Dyspepsia	4 (10%)	0	0	0
Edema limbs	4(10%)	0	0	0
Non-cardiac chest pain	4 (10%)	0	0	0
Paresthesia	4 (10%)	0	0	0
Weight gain	4(10%)	0	0	0
Creatinine increased	4(10%)	0	0	0
Skin infection	2(5%)	1(3%)	0	0
Blood bilirubin increased	1(3%)	1(3%)	0	0
Febrile neutropaenia	0	1(3%)	0	0
Heart failure	0	1(3%)	0	0
Hypophosphataemia	0	1(3%)	0	0
Intracranial haemorrhage	0	0	0	1(3%)

Data are n (%). All-cause grade 1–2 adverse events occurring in at least 10% of patients and all grade 3,4, and 5 events are shown, irrespective of the relationship to protocol therapy.